Aurelian Radu, PhD
- ASSOCIATE PROFESSOR | Cell, Developmental & Regenerative Biology
Research Topics:
Angiogenesis, Anti-Tumor Therapy, Cancer, Endothelial CellsEducation
National Diploma Physics and Biophysics, University of Bucharest
PhD, Institute of Cellular Biology and Pathology
FSHR as a marker of tumor blood vessels
My research work is focused on a marker of tumor blood vessels, the Follicle Stimulating Hormone Receptor (FSHR), which is present in all major tumor types that we investigated, while having a very limited presence in normal tissues and organs.
We are evaluating the feasibility of FSHR blood tests, to detect the presence of tumors and to monitor their response to therapies based on FSHR released in blood. We are also working to elucidate the role of FSHR in cancer progression. Another area of investigation is the use of FSHR as a target for directing imaging and therapeutic agents into tumors.
Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Vu Hai M, Ghinea N. Blood vessel endothelium expresses FSHR in a wide range of human cancers . New Engl J Med 2010 Oct; 363(17): 1621-1630.
Siraj MA, Pichon C, Radu A, Ghinea N. Endothelial FSH receptor in primary kidney cancer correlates with subsequent response to Sunitinib. J Cell Mol Med 2012; 16(9): 2010-16.
Siraj MA, Desestret V, Antoine M, Fromont G, Huerre M, Sanson M, Camparo P, Pichon C, Planeix F, Gonin J, Radu A, Ghinea N. Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases.. BMC Cancer. 2013; 13: 246-252.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Radu did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.